• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
              Advocacy & Research for Unlimited Lifespans

Adverts help to support the work of this non-profit organisation. To go ad-free join as a Member.


Eidos Therapeutics


  • Please log in to reply
No replies to this topic
⌛⇒ MITOMOUSE has been fully funded!

#1 caliban

  • Admin, Advisor, Director
  • 8,953 posts
  • 1,807
  • Location:UK

Posted 21 March 2018 - 02:06 PM

Transthyretin (TTR) is a relatively abundant protein in the blood, named after its role in transporting thyroxine and retinol. Due to a genetic mutation or environmental factors, the protein can become unstable and misfold, causing it to accumulate as toxic amyloid aggregates in the heart or peripheral nerves.

Eidos aims to halt TTR amyloidosis by treating the root cause of the disease, destabilized and misfolded TTR. Inspired by a natural TTR mutation that protects carriers from the disease, Eidos is developing a small molecule (named AG10) that binds and stabilizes TTR in the blood. Pre-clinical studies have shown promising data for safety and efficacy, paving the way for clinical testing.





PARENT: https://bridgebio.com/


1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users